Self-injection refers to the act of administering medication or other substances into one's own body using a needle and syringe. Self-injection is a common practice for individuals who require regular injections of medication, such as insulin for people with diabetes.
Self-injection can be done in various parts of the body, including the abdomen, thighs, buttocks, and arms. The injection site and technique may vary depending on the type of medication and the individual's personal preference.
Self-injections are starting to gain popularity as a convenient method of delivering medication therapy at home. People with arthritis and diabetics who depend on insulin, for example, frequently use injectable medication since it is a simple and dependable way to self-administer medications.
The Global Self-Injection Market was valued at 6.97 billion USD in 2022, and it is expected to reach 18.01 billion USD by 2030 with a CAGR of 10.8% in the forecast period of 2023-2030. The self-injection market is driven by several factors, including:
Increasing prevalence of chronic diseases: Self-injection is becoming a popular method for the treatment of chronic diseases such as diabetes, multiple sclerosis, and rheumatoid arthritis. The rising incidence of these diseases is fueling the demand for self-injection devices.
Technological advancements in self-injection devices: The development of innovative self-injection devices that are easy to use, portable, and accurate is driving the growth of the self-injection market. Examples of such devices include autoinjectors and pen injectors.
Growing demand for home healthcare: There is an increasing trend towards home healthcare, as patients prefer to receive treatment in the comfort of their homes. This has led to the development of self-injection devices that are easy to use and can be administered by patients themselves or their caregivers.
Key market players in Global Self-Injection Market include Elcam Medical, Bespak, Sanofi, Sandoz International Gmbh, Unilife Corporation, West Pharmaceutical Services, Inc, Pfizer Inc., Impax Laboratories, Inc., Penjet Corporation, Crossject Needle-Free Injection Systems, Terumo Corporation, Antares Pharma, Becton, Dickinson and Company, Gerresheimer AG, Mylan N.V, Novo Nordisk, Owen Mumford Ltd, Pharmajet, SHL Group, Ypsomed Wilhelm Haselmeier Gmbh & CO. KG, and Wilhelm Haselmeier Gmbh & CO. KG.
Some of the recent developments are: NuGen Medical Devices' InsuJet needle-free injection system and accessories were authorized by Health Canada in December 2021. Over the anticipated period, these actions accelerate market expansion.
The self-injection market can be segmented based on product type and application.
Based on Product type, Pen injectors, auto-injectors, and wearable injectors are the three product categories into which the global market for self-injection devices has been divided. According to research, it is anticipated to be the most popular product category because of the diabetic applications for pen injectors, their accessibility, and their low price. During the projection period, the pen injectors segment is anticipated to grow because of the widespread availability of these devices.
Based on Application type, one of the top parts is cancer. During the projection period, it is expected that the rising cancer incidence would significantly increase demand for self-injection devices. For instance, the National Cancer Institute estimates that in 2020, there will be 1,806,590 new cancer cases diagnosed in the United States. The category is anticipated to develop as a result of cancer patients' increasing tendency to self-administer their medications.
During the projected period, North America is anticipated to lead the global market. In the upcoming years, the market in North America is anticipated to be driven by a high level of disposable self-injection device consumption, a quick rise in the number of people with diabetes and rheumatoid arthritis, and an increase in home health care. Furthermore, the patent expirations of popular biologic pharmaceuticals in the United States, the rise in demand for biosimilars, and the projected introduction of new products are all expected to contribute to the market for self-injection devices in the region's growth.
The market in Asia Pacific is expected to grow at a notable CAGR. During the forecast period, it is expected that rising awareness of various chronic diseases, rapidly evolving healthcare systems in developing nations like China and India, and well-established pharmaceutical markets in Japan will drive the self-injection devices market in the Asia Pacific.
The self-injection market is a rapidly growing industry driven by several factors, including the increasing prevalence of chronic diseases, technological advancements in self-injection devices, growing demand for home healthcare, increasing awareness about the benefits of self-injection, and government initiatives to promote self-injection. With the development of innovative self-injection devices and the increasing adoption of self-injection as a preferred method of drug delivery, the self-injection market is expected to continue to grow in the coming years. This growth presents opportunities for healthcare companies to develop new and innovative products and expand their market share in this burgeoning industry.